Hong-Hu Zhu Selected Research

Aclarubicin

1/2020	CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study.
11/2016	Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
5/2016	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
11/2013	Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hong-Hu Zhu Research Topics

Disease

21	Acute Promyelocytic Leukemia 05/2022 - 02/2007
20	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2022 - 07/2006
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 07/2006
5	Neoplasms (Cancer) 07/2021 - 12/2013
5	Leukemia 01/2021 - 05/2016
4	Residual Neoplasm 01/2019 - 02/2012
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2016 - 06/2003
3	Infections 08/2022 - 11/2013
3	Hematologic Neoplasms (Hematological Malignancy) 05/2022 - 04/2016
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021 - 01/2020
3	Thrombocytopenia (Thrombopenia) 01/2018 - 10/2015
2	Fever (Fevers) 08/2022 - 11/2013
2	Philadelphia Chromosome 01/2022 - 01/2020
2	Leukocytosis (Pleocytosis) 01/2020 - 10/2017
2	Melanoma (Melanoma, Malignant) 12/2017 - 04/2017
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2013 - 07/2006
1	Carcinogenesis 05/2022
1	Hyperthermia 07/2021
1	Dyslipidemias (Dyslipidemia) 01/2020
1	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 01/2020
1	Disseminated Intravascular Coagulation 01/2018
1	Multiple Myeloma 12/2017
1	Testicular Neoplasms (Testicular Cancer) 12/2017
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2017
1	Wilms Tumor (Wilm's Tumor) 05/2016
1	Hemorrhage 02/2007

Drug/Important Bio-Agent (IBA)

15	ArsenicIBA 07/2021 - 08/2013
12	Arsenic Trioxide (Trisenox)FDA Link 05/2022 - 11/2013
12	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2022 - 08/2013
4	venetoclaxIBA 08/2022 - 01/2020
4	AclarubicinIBA 01/2020 - 11/2013
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 11/2013
3	Oncogene Proteins (Oncogene Protein)IBA 05/2022 - 11/2016
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 11/2013
3	realgar-indigo naturalisIBA 01/2018 - 11/2013
3	AntigensIBA 12/2017 - 06/2003
2	Hemoglobins (Hemoglobin)IBA 08/2022 - 02/2007
2	Prednisone (Sone)FDA LinkGeneric 01/2022 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 07/2021 - 07/2006
2	LipidsIBA 01/2020 - 01/2020
2	HomoharringtonineIBA 11/2016 - 05/2016
2	Imatinib Mesylate (Gleevec)FDA Link 01/2016 - 09/2013
2	Messenger RNA (mRNA)IBA 09/2013 - 02/2007
1	Azacitidine (5 Azacytidine)FDA Link 08/2022
1	Decitabine FDA Link 08/2022
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 05/2022
1	ponatinibIBA 01/2022
1	Co-Repressor ProteinsIBA 07/2021
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 07/2021
1	UbiquitinIBA 07/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	Drug CombinationsIBA 01/2021
1	LeptinIBA 01/2020
1	Dasatinib (BMS 354825)FDA Link 01/2020
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2020
1	ResistinIBA 01/2020
1	Insulin-Like Growth Factor Binding Protein 3IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2019
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2018
1	Alanine Transaminase (SGPT)IBA 01/2018
1	Dacarbazine (DIC)FDA LinkGeneric 01/2018
1	Bortezomib (Velcade)FDA Link 12/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2016
1	Nuclear Pore Complex Proteins (Nucleoporins)IBA 04/2016
1	Core Binding Factors (Core-Binding Factor)IBA 12/2014
1	Sulfides (Thioethers)IBA 11/2013
1	Transaminases (Aminotransferases)IBA 11/2013
1	Tyrosine Kinase InhibitorsIBA 09/2013
1	NucleophosminIBA 07/2013
1	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 02/2007
1	PhosphotyrosineIBA 07/2006
1	CytokinesIBA 06/2003

Therapy/Procedure

10	Drug Therapy (Chemotherapy) 12/2021 - 06/2012
10	Therapeutics 07/2021 - 05/2013
6	Hematopoietic Stem Cell Transplantation 01/2021 - 02/2012
2	CAG protocol 01/2020 - 11/2013
1	Transplantation 01/2020
1	Haploidentical Transplantation 01/2019
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 12/2016
1	Consolidation Chemotherapy 05/2016
1	Induction Chemotherapy 11/2013
1	Stem Cell Transplantation 06/2012